Journal of Medicinal Chemistry · 2023 · 28 citations · 56 references
PharmacyChemistryMedicinal ChemistryCancer PharmacologyDrug DesignDrug DiscoveryCovalent Drug DesignCovalent Inhibitor DesignEnzyme InhibitionGlutathione ConjugationLigand BindingAqueous StabilityCovalent InhibitorsCysteine-targeted InhibitorsReactivityReversible Covalent ChemistryReversible Covalent InhibitionReversible Covalent InhibitorsTargeted Covalent Inhibitors
The choice of an appropriate electrophile is crucial in the design of targeted covalent inhibitors (TCIs). In this report, we systematically investigated the glutathione (GSH) reactivity of various haloacetamides and the aqueous stability of their thiol adducts. Our findings revealed that dihaloacetamides cover a broad range of GSH reactivity depending on the combination of the halogen atoms and the structure of the amine scaffold. Among the dihaloacetamides, dichloroacetamide (DCA) exhibited slightly lower GSH reactivity than chlorofluoroacetamide (CFA). The DCA–thiol adduct is readily hydrolyzed under aqueous conditions, but it can stably exist in the solvent-sequestered binding pocket of the protein. These reactivity profiles of DCA were successfully exploited in the design of TCIs targeting noncatalytic cysteines of KRAS G12C and EGFR L858R/T790M . These inhibitors exhibited strong antiproliferative activities against cancer cells. Our findings provide valuable insights for designing dihaloacetamide-based reversible covalent inhibitors.
56
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
J.M. Ostrem, Ulf Peters, Martin L. Sos et al. · Nature · 2013 · 2.5K citations · Full text
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.3K citations
Medicine, Oncology, Pharmacology +14
Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +11